Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMC589354
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TMC589354 is an investigational small molecule developed by Johnson & Johnson as part of the PEPI family of compounds. It was designed not for direct antiviral activity, but to enhance the pharmacokinetic profile of other drugs, specifically HIV-1 protease inhibitors such as TMC310911. In clinical studies, TMC589354 was evaluated for its safety, tolerability, and ability to boost plasma levels of co-administered drugs in healthy volunteers. The compound reached Phase 1 clinical trials but development has since been discontinued[1][3][4][5].
Beyond the preview
Go deeper on TMC589354.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMC589354.